Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.
Several studies implicate that lung cancer progression is governed by the interaction between epidermal growth factor receptor (EGFR) signaling and protein kinase C (PKC) pathways. Combined the targeting of EGFR and PKC may have an additive or synergistic effects in lung cancer treatment. The aim of...
Main Authors: | Miao He, Zhaoying Yang, Le Zhang, Changlong Song, Youjun Li, Xingyi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5388488?pdf=render |
Similar Items
-
Erlotinib in Patients with Brain Metastases for Non-small Cell Lung Cancer
by: Jinming YU, et al.
Published: (2009-12-01) -
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
by: Boutsikou E, et al.
Published: (2013-03-01) -
Experience with erlotinib in the treatment of non-small cell lung cancer
by: Lorenza Landi, et al.
Published: (2015-08-01) -
Erlotinib for the treatment of relapsed non-small cell lung cancer
by: C McLeod, et al.
Published: (2009-06-01) -
A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
by: Jinhui TIAN, et al.
Published: (2009-12-01)